Isaac Kinde

Cologuard Plus™, our next-generation Cologuard® test, is now FDA approved. With 95% sensitivity for colorectal cancer and 43% sensitivity for advanced precancers, it sets a new performance standard for noninvasive screening. Read the full press release: bit.ly/3ZXEVf4

We’re thrilled to announce that Resolution Bioscience will be joining the Exact Sciences family. This acquisition will further our mission by adding complementary capabilities to our growing portfolio. exactsciences.com/newsroom/press…

March 1st marks the start of #ColorectalCancerAwarenessMonth. We look forward to celebrating our patients, sharing some of their stories, and working to raise awareness about colorectal cancer and its impact.

In the fight against cancer, the challenges and accomplishments of the Black community are often overlooked. This #BlackHistoryMonth, read about five leaders, including our own @IsaacKinde, who are working to increase equity: exas.co/3YVlWyu @katiecouric

We are thrilled to expand Exact Sciences’ presence in San Diego. Our focus for this facility will be to develop next-generation cancer diagnostics to help patients and physicians make better treatment decisions.

This #WorldCancerDay, we’re using this space to share more from these partners and ways to get involved. See more in our Twitter Moment: twitter.com/i/events/14896…

We are excited to announce that we are now a part of the @ExactSciences team. We look forward to continuing our work to help make genetic and hereditary cancer testing available to more patients, together. #ChangingLivesTogether ow.ly/rXJI50Hqx1z

We’re thrilled to welcome Everett Cunningham to our leadership team as Chief Commercial Officer. Learn more about his impressive background here: exactsciences.com/about/manageme…

Katie Couric sits down with CEO Kevin Conroy to discuss our mission to eradicate cancer and how our teams are working to make it possible to detect cancers earlier. ms.spr.ly/6018Xgb4u @katiecouric

@AdamZiegel Thanks Adam! Very much appreciate your help in building the awesome team we have today

@BhanSeema @ExactSciences How kind of you! Love how you’re enabling our mission from the policy perspective. And grateful for you laughing at my jokes ;)

@IsaacKinde is the best of the best and he is super fun and funny too. What a privilege to work with you. @ExactSciences

@KevinConroyCEO @ExactSciences Thanks Kevin and Exact! I’m so humbled by your kind words. Looking forward to helping Exact achieve our mission

👏👏👏 and a great human being too!

Honored to be included in this group of healthcare industry leaders

Congratulations to Dr. Karlo Perica of @sloan_kettering, recipient of the 2021 SITC-Bristol Myers Squibb (@bmsnews) Postdoctoral Cancer Immunotherapy Translational Fellowship, a 2-year, $200K SITC Fellowship! sitcancer.org/funding/fellow…

This is the best explanation of the Covid Vaccine I’ve ever heard.

Semi Trotto, General Manager of Exact Sciences’ Thrive business unit, will be joining @Pharma_Intell panel of biopharma and med tech leaders to discuss leadership in times of uncertainty. Register here to join the webinar: ms.spr.ly/6011VvYTd

70% of cancers do not currently have a screening test. Sue's story shows why we must deliver new solutions for early detection, and how multi-cancer tests hold promise to lead the way. Read here via @KatieCouric: ms.spr.ly/6019V0Vq5

Together with @BloombergDotOrg, we are launching the Vivien Thomas Scholars Initiative, a $150 million effort to increase diversity in #STEM PhD programs, in partnership with HBCUs and MSIs. hub.jhu.edu/2021/05/11/viv…

Dr. Bert Vogelstein’s vision for the future of screening inspires our work every day to advance our multi-cancer earlier detection blood test. ms.spr.ly/6013VUHUB

This lung cancer awareness month, our co-founder and head of research & innovation @IsaacKinde emphasizes the importance of screening & the significant impact our blood test had in detecting lung cancer in our DETECT-A study. The future of #earlierdetection is within reach. #LCAM